2025 CPT Code Revisions Will Have a Significant Impact on the Classification of Retroperitoneal Sarcoma Resection

BACKGROUND: In 2025, the AMA revised CPT codes for intra-abdominal tumor resections, replacing the greater than 10 cm category with 3 new categories: 10.1 to 20 cm, 20.1 to 30 cm, and greater than 30 cm. We hypothesized these codes would better reflect case complexity and improve alignment between operative burden and reimbursement. STUDY DESIGN: This retrospective cohort study used the National Cancer Database (2004 to 2022) to identify adult patients who underwent resection of retroperitoneal sarcoma. Patients were classified using old and revised CPT codes, with a 20 cm threshold identifying tumors eligible for recoding. Anticipated changes in work relative value units were calculated using weighted averages. Logistic regression assessed annual trends in tumors greater than 20 cm. Paired t -tests and chi-square tests compared the demographics and proportions of sarcomas greater than 20 cm resected across clinical settings. RESULTS: Of 12,940 patients, 72.1% (n = 9,326) fell under the greater than 10 cm category per old guidelines. With 2025 revisions, 37% (n = 4,789) qualified for different CPT codes due to tumors greater than 20 cm, leading to an expected 30.4% relative increase (30.1 to 39.3) in the average work relative value unit. Most sarcomas greater than 20 cm were resected at Academic or Research Programs (62.7%, p < 0.001). Patients with tumors greater than 20 cm were typically insured privately (45.8%) or by Medicare (40.6%) without significant differences in insurance type between the 10 to 20 cm and greater than 20 cm groups (p = 0.4). CONCLUSIONS: Revised CPT codes better capture the heterogeneity and surgical complexity of retroperitoneal sarcomas. These changes will likely have the greatest impact in academic settings, with implications for all insurers.